Other investigators have described partly significantly differing data, where Napsin A positivity was seen in up to 83% (five/six) of esophageal adenocarcinomas and in up to 40% (two/five) of gastric adenocarcinomas when polyclonal antibodies were used; however, no positive immunohistochemical reaction was observed in the same tumor cases when a monoclonal anti-Napsin A antibody was applied [34,35]. This evidence concerns the gene NAPSA and esophageal adenocarcinoma.